EP Patent

EP3099295A1 — Dose adjustment in combination therapy of hepatitis c

Assigned to AbbVie Inc · Expires 2016-12-07 · 9y expired

What this patent protects

This application features dose adjustment for drugs co-administered with Compound 1, Compound 2 and/or Compound 3.

USPTO Abstract

This application features dose adjustment for drugs co-administered with Compound 1, Compound 2 and/or Compound 3.

Drugs covered by this patent

Patent Metadata

Patent number: EP3099295A1
Jurisdiction: EP
Classification: —
Expires: 2016-12-07
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.